Top Page
Proteomics International Laboratories Ltd.
(Sydney:PIQ)
Proteomics International Laboratories Ltd. (PIQ) vs. iShares MSCI Australia ETF (EWA)
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Proteomics International Laboratories Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.50M | 960.39K | 892.14K | 730.34K | 1.49M | 1.31M |
| Gross Profit | 1.46M | 960.39K | -1.12M | -1.62M | -568.62K | 497.08K |
| EBITDA | -6.74M | -10.00M | -8.40M | -7.55M | -4.56M | -2.77M |
| Net Income | -7.11M | -8.11M | -6.38M | -6.23M | -4.97M | -2.86M |
Balance Sheet | ||||||
| Total Assets | 7.02M | 14.78M | 10.88M | 10.08M | 5.40M | 8.60M |
| Cash, Cash Equivalents and Short-Term Investments | 5.33M | 11.04M | 6.64M | 6.03M | 2.11M | 5.60M |
| Total Debt | 247.67K | 277.74K | 316.39K | 64.09K | 0.00 | 69.05K |
| Total Liabilities | 1.74M | 1.81M | 1.63M | 1.75M | 2.00M | 990.19K |
| Stockholders Equity | 5.46M | 13.17M | 9.41M | 8.38M | 3.39M | 7.61M |
Cash Flow | ||||||
| Free Cash Flow | -5.51M | -6.63M | -6.00M | -6.91M | -3.67M | -2.41M |
| Operating Cash Flow | -5.46M | -6.60M | -5.59M | -5.69M | -3.54M | -2.21M |
| Investing Cash Flow | -46.19K | -29.65K | -388.02K | -1.17M | -129.46K | -191.00K |
| Financing Cash Flow | 5.87M | 11.03M | 6.59M | 10.77M | 176.10K | 5.64M |
Proteomics International Laboratories Ltd. Technical Analysis
Proteomics International Laboratories Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$85.06M | -1.40 | -100.67% | ― | 1114.27% | 85.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$104.81M | -11.34 | -71.87% | ― | 7.65% | -19.13% | |
50 Neutral | AU$92.53M | -9.67 | -49.72% | ― | ― | 10.78% | |
45 Neutral | AU$8.84M | ― | -469.35% | ― | ― | 46.28% | |
44 Neutral | AU$196.64M | -7.44 | ― | ― | ― | 0.66% |
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International Laboratories has strengthened its US footprint after its Irvine, California reference laboratory secured accreditation from the College of American Pathologists, a quality benchmark regarded as the gold standard and more demanding than existing CLIA certification. Alongside the accreditation, the company has commissioned a new mass spectrometry platform to support commercialisation of its Promarker suite of precision diagnostic blood tests, initially focusing on establishing the PromarkerEso assay for esophageal adenocarcinoma ahead of a planned US launch in 2026, while also positioning the facility to run future tests such as PromarkerEndo for endometriosis, reinforcing Proteomics International’s positioning as a leading provider of high-quality precision diagnostics.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the publication of a peer-reviewed study in the Internal Medicine Journal, demonstrating the clinical utility of their PromarkerD test in Australia. The study showed that PromarkerD significantly influences clinical decision-making by prompting earlier initiation of renoprotective therapies and reducing the use of nephrotoxic drugs among patients at risk of diabetic kidney disease. With 89% of surveyed physicians believing in the test’s potential to improve clinical outcomes, the findings support PromarkerD’s role in enhancing treatment strategies for the 1.5 million Australians with type 2 diabetes, potentially leading to better patient management and reduced healthcare costs.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the commercial launch of its precision diagnostics services, marking a significant milestone in the company’s operations. This move is expected to enhance the company’s market positioning in the healthcare sector, potentially offering new opportunities for growth and development, and providing stakeholders with insights into the company’s future trajectory.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd responded to an ASX price query, clarifying that recent trading activity in its securities is likely due to several significant announcements. These include the US Medicare setting a reimbursement price for their PromarkerD test, which supports their US launch strategy, and new data on their OxiDx test indicating its potential to improve racehorse performance. The company has also achieved milestones such as clinical certification for its Australian diagnostics laboratory and initial sales of PromarkerD and PromarkerEso in Australia. These developments have likely contributed to increased investor interest.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.38 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced that the US Centers for Medicare & Medicaid Services (CMS) has set a reimbursement price for their PromarkerD test, a predictive diagnostic for diabetic kidney disease, at $390.75. This decision is a significant milestone for the company, enhancing their US launch strategy by facilitating broader patient access and strengthening discussions with private payers. The PromarkerD test, which can predict diabetic kidney disease up to four years before symptoms appear, has the potential to improve care for over 32 million adults in the US with diabetes, reduce healthcare costs, and drive adoption and commercial partnerships.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the quotation of 50,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code PIQ. This move is part of the company’s ongoing efforts to enhance its market presence and provide additional value to its stakeholders by leveraging its expertise in proteomics.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the issuance of new unquoted equity securities, specifically options expiring in 2028 and 2029. This move may impact the company’s financial strategy and provide additional resources for its ongoing projects, potentially strengthening its position in the biotechnology sector.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced a change in the director’s interest, specifically regarding Neville Gardiner’s indirect holdings. The announcement detailed the expiration of 250,000 unquoted options that were not exercised, impacting the director’s indirect interest holdings. This change reflects the company’s ongoing management of its securities and may influence stakeholder perceptions of the company’s governance practices.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the cessation of 375,000 securities under the ASX code PIQAZ, which expired on November 24, 2025, without being exercised or converted. This announcement may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s financial strategies and market positioning.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced that all resolutions at their Annual General Meeting were passed by poll. This outcome reflects strong shareholder support and may positively influence the company’s strategic initiatives and governance, potentially enhancing its position in the medical technology sector.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced at its Annual General Meeting that Richard, the founding Managing Director, will retire in early 2026 after 25 years with the company. The recruitment process for his successor is well underway, ensuring a smooth leadership transition. The company acknowledged Richard’s significant contributions and the promising future opportunities for Proteomics International.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced its participation in the Bell Potter Healthcare Conference 2025, where Dr. Richard Lipscombe will present on the company’s advancements. This engagement underscores the company’s commitment to showcasing its innovative diagnostic solutions, potentially enhancing its industry position and stakeholder engagement.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has bolstered its cash reserves with a $2.2 million R&D tax incentive for the 2024-25 financial year. This funding supports the commercialization of their diagnostic tests, including Promarker®D for Diabetic Kidney Disease and Promarker®Endo for Endometriosis, as well as their ongoing R&D efforts. The rebate, part of the Australian Government’s initiative to encourage beneficial research, highlights the company’s commitment to advancing its diagnostic pipeline and strengthening its market position.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has received a $500,000 grant from the Western Australian Government to support the commercialization of PromarkerEndo, a pioneering blood test for diagnosing endometriosis. This funding will aid in regulatory, marketing, and partnership efforts, addressing the global health challenge of endometriosis, which affects one in nine women. The test offers a non-invasive alternative to current diagnostic methods, potentially transforming women’s healthcare by reducing the average seven-year diagnosis time, and is expected to launch in Australia in the second half of 2025.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has achieved significant milestones, including receiving ISO 15189 certification for its Australian laboratory operations, which supports the commercialization of its precision diagnostic tests like PromarkerD and PromarkerEso. The company is expanding its market presence with the national launch of PromarkerD for diabetic kidney disease prediction and PromarkerEso for esophageal cancer diagnosis in Australia, alongside preparations for the PromarkerEndo test for endometriosis. These developments, coupled with a strategic go-to-market approach embracing telehealth trends, position the company for potential partnerships and revenue growth in the precision diagnostics sector.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced its upcoming Annual General Meeting, scheduled for 21 November 2025. The company has opted for digital distribution of the Notice of Meeting, encouraging shareholders to access documents online and submit proxy votes electronically, reflecting a modern approach to shareholder engagement.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the appointment of Vicki Robinson as a new director, effective from October 14, 2025. The initial director’s interest notice indicates that Robinson currently holds no securities in the company, which suggests a neutral impact on the company’s stock ownership structure. This appointment could potentially influence the company’s strategic direction, given Robinson’s role on the board.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has expanded its collaboration with the University of Melbourne and the Royal Women’s Hospital to enhance the PromarkerEndo blood test for diagnosing endometriosis. This partnership aims to provide additional clinical validation and develop a next-generation tissue-specific test, addressing a significant global health need. The collaboration seeks to reduce the average seven-year diagnostic delay for endometriosis, potentially transforming women’s healthcare by offering a non-invasive diagnostic option. The agreement includes commercial terms granting Proteomics International an exclusive license to commercialize new intellectual property developed under the project.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the appointment of Ms. Vicki Robinson as an independent non-executive director. With over 20 years of experience in executive and governance roles, Ms. Robinson is expected to enhance the company’s strategic and decision-making capabilities. Her appointment comes at a crucial time as Proteomics International rolls out its leading diagnostic products, which have the potential to transform the management of chronic conditions such as diabetic kidney disease, endometriosis, and esophageal cancer.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the issuance of 375,000 unquoted equity securities, specifically options expiring on June 6, 2027, with an exercise price of $0.555. This issuance is part of a previously announced transaction, and these securities are not intended to be quoted on the ASX. The move reflects the company’s ongoing efforts to manage its equity and financial strategy, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.